CN1813916A - Compound chinese medicine formulation for treating common cold and its preparing process - Google Patents
Compound chinese medicine formulation for treating common cold and its preparing process Download PDFInfo
- Publication number
- CN1813916A CN1813916A CNA2005100956209A CN200510095620A CN1813916A CN 1813916 A CN1813916 A CN 1813916A CN A2005100956209 A CNA2005100956209 A CN A2005100956209A CN 200510095620 A CN200510095620 A CN 200510095620A CN 1813916 A CN1813916 A CN 1813916A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- doubly
- group
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 7
- 201000009240 nasopharyngitis Diseases 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 title description 2
- 238000009472 formulation Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 241000746375 Andrographis Species 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 11
- 241000233838 Commelina Species 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 81
- 229940079593 drug Drugs 0.000 claims description 44
- 206010022000 influenza Diseases 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000008517 radix Trichosanthis Substances 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 11
- 241000555712 Forsythia Species 0.000 claims description 8
- 235000014435 Mentha Nutrition 0.000 claims description 8
- 241001072983 Mentha Species 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 51
- 210000004072 lung Anatomy 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 241000700605 Viruses Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 241000712461 unidentified influenza virus Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 230000003203 everyday effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 229940100050 virazole Drugs 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- 208000015220 Febrile disease Diseases 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 108010001062 polysaccharide-K Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 206010008531 Chills Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 229960001660 histamine phosphate Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241001092500 Photinia x fraseri Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 210000005182 tip of the tongue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000003851 azoles Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000009916 yin-huang Substances 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a Chinese medicine preparation for curing common cold and its preparation process. It is made up by using 6 Chinese medicinal materials of forsythia fruit, andrographis, notoplerygium root, dayflower, peppermint and trichosanthes root through a certain preparation process. Besides, said invention also provides the concrete steps of said preparation process.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, be specifically related to a kind of Chinese medicine for the treatment of flu, the invention still further relates to the preparation technology of this Chinese medicine.
Background technology
Flu is common exogenous diseases.According to statistics, the adult is annual takes place 1～3 time, 2～7 respiratory tract diseases of the annual generation of child, and wherein number is to be caused by virus mostly.Flu is worker's absence from duty, student's common cause absent from school.Flu not only influences human operate as normal and life health risk, has also correspondingly consumed a large amount of expenses.Flu is also very big to the harm that anemia of pregnant woman, old man and child cause, and complications such as pneumonia and secondary infection etc. due to it have certain mortality rate.
At present, western modern medicine mainly takes anti symptom treatment, vaccination, passive immunity and antiviral therapy etc. to prevent and treat method to catching a cold.Because the cold virus kind is changeable different big, specific immunity is not consolidated, and except having certain protective rate at flu-prevention inoculation trivalent purified vaccine, still is not used in the vaccine of therapeutic purposes.Though use antiviral drugs certain curative effect is arranged, this type of medicine (as amantadine, rimantadine etc.) side effect is obvious, and easily produces the drug resistance strain.Approaching because of its effective dose with the dosage that has side effects, produce curative effect and cause a lot of untoward reaction often.In order to make antiviral agents or cold vaccine bring into play better curative effect, there is the people that medicine is directly sprayed into nasal cavity, but, certain difficulty arranged so keep enough drug concentration in the part because of nose cilium energy eliminating particle sample material.Multiple reason becomes safety that antiviral agents uses and effectiveness a difficult problem to be solved.We can say that flu is the disease that present doctor trained in Western medicine still lacks effective Therapeutic Method.
And from the Chinese medicine category, because motherland's medical science is with a long history with treatment to the understanding of flu, it progressively forms with perfect according to the continuous development of Chinese medicine rationale and the abundant and accumulation of clinical experience.Theory of Chinese medical science thinks that flu mainly defended due to the fur by the ailment said due to cold or exposure of six climate exopathogens invasion and attack lung, with abrupt change of climate, cold temperature is not normal and factor such as physical strength is relevant." should warm up during the spring and anti-cold, should heat during the summer and anti-cold, should be cold during the autumn and anti-heat, should tremble with fear during the winter and anti-warm " (" disorder of QI duke or princess under an emperor during the General Treatise on the Cause and Symptoms of Diseases ") all can be caused a disease.Virus is hurted sb.'s feelings during gas when non-folder, then easilier causes morbidity and be not limited to seasonality that the state of an illness is multiple, often infects popular each other.Defending the table discord is the basic pathogenesis of flu with impaired depurative descending of lung QI.Because four o'clock six gas differences and human quality's difference, the syndrome of clinical manifestation have the card of the double folder of wind and cold, wind heat and heat-damp in summer.In the course of disease and the conversion of visible cold and heat or mixed.As when experiencing row epidemic disease poison then the state of an illness is multiple, even its patient is given birth in sudden change.On dialectical basis, abide by the justice of " it has evil person, and routed shape is thought antiperspirant, and it is at skin person, inducing diaphoresis " (" element asks YIN YANG classification of natural phenomena big opinion "), be principle to separate the expression heresy.According to the heightened awareness of theory of Chinese medical science to flu, on the dialectical basis that combines with differential diagnosis of diseases, use the respective party medicine, often can obtain significant curative effect.The Chinese patent medicine of more existing in the market treatment flu such as injection of Radix Bupleuri, YINQIAO sheet, YINHUANG ZHUSHEYE etc.But generally, the Chinese patent medicine of treatment flu is also fewer, and the market share is also less relatively, and the curative effect of some medicine neither be very desirable.Therefore, develop pure Chinese medicine anti-cold medicine evident in efficacy, that toxic and side effects is little, reduce the threat of flu, have than great social significance to human health.
Summary of the invention
The purpose of this invention is to provide the Chinese medicine preparation that a kind of treatment evident in efficacy, that toxic and side effects is little is caught a cold.
Another object of the present invention provides the preparation technology of above-mentioned Chinese medicine preparation.
The present invention forms according to the Chinese medical theory prescription.On the Chinese medicine, as far back as " interior warp " record of similar flu is arranged promptly, primary symptom is sweating, headache, heavy sensation of the body, aversion to cold etc.And think that its cause of disease mainly is due to the heresy that is affected by the cold." element ask bone chamber opinion " said: " wind from outside go into, make us cold with shivering, sweating is had a headache, the heavy sensation of the body aversion to cold." name of flu, head sees the Song dynasty " formulary of peaceful benevolent dispensary cure the wound the cold pure blessing side of adding newly ", has under " Ginseng Decoction for Nourishing Stomacs " tea: " flu on the whole, ancients are diaphoresis person gently ...Since then, the name of disease of flu is continued to use always.The Qing Dynasty can be widely current in a period because the development of the theory of epidemic febrile disease recognizes that some flu has popularity, old children irrespective of sex, and the symptom multiphase-fenton seemingly with to experience seasonal pathogen relevant, claims influenza, the state of an illness is more generally attached most importance to.Flu is mainly defended due to the fur by the ailment said due to cold or exposure of six climate exopathogens invasion and attack lung, and is relevant with abrupt change of climate, cold temperature factors such as power not normal and body constitution.Song's Yang Shiying is thought flu for experiencing due to the ailment said due to cold or exposure, and it is pathogenic that Sui's Chao Yuanfang (550-630 A.D.) has proposed affection due to external wind and heat again.Aspect the treatment of flu, Chinese Zhang Zhongjing has been used the method for relieving the exterior syndrome by diaphoresis, and first Zhu Dan small stream is to the hot cool two big method of treatment of the treatment apportion of flu, and pungent and cool prescription with moderate action Lonicerae and Forsythiae Powder of clear Wu's a kind of jade " the epidemic febrile disease bar is debated " and pungent and cool prescription with mild action SANGJU YIN are specialized the relieving the exterior syndrome with drugs of pungent in flavor and cool in nature method.Complete substantially to the understanding of the reason of flu, method, side, medicine to the Qing Dynasty, the principle of treatment of flu is when to disperse.Modern age, many understanding and the experience of doctor family were also further enriched understanding to catching a cold.
We's adaptation disease is an anemopyretic cold.Promptly cure mainly common cold due to wind heat, show as the not aversion to cold that generates heat, or slight chill, headache, thirsty, cough, pharyngalgia, red tip of the tongue, white and thin fur or BOHUANG, floating and rapid pulse etc.The cause of disease of disease is the heresy of wind heat, and disease is positioned at lung and defends.Lung controlling breathing, the lung position is the highest, has one's ideas straightened out in nose, closes fur outward, and with to defend gas phase logical, the wheat of main the whole body.Pathogenic warmth is gone into from mouth and nose, on violate in lung, the cause of disease is in heat, so the exterior symptoms fever without chill; Lung qi is by strongly fragrant, can not declare to send out and defend gas and reach table, so slight chill; Lung qi is by strongly fragrant, and the lung merit is impaired, so be cough; Headache is steamed due to last for heat, and thirsty is the injured symbol of body fluid.Larynx is that lung is an ingredient, and wind heat is attacked lung, and functional activities of the body fluid is unfavorable,, hinder in lung system, so have sore throat; So heat in upper-JIAO is red tip of the tongue; Epidemic febrile disease from the beginning of, so yellow and thin fur, floating and rapid pulse.To sum up, this card is defended because of having cold and heat to cough to know the disease being located in the lung; Know characteristic of disease because of its more fever with less chills and belong to heat; Because of the thirsty little damaged of body fluid of knowing is arranged.The card ask because of, this is that the warm pathogen tend to attack the upper orifices heresy is defended at lung.Epidemic febrile disease from the beginning of, evil defend at lung, clean suitable dispelling wind and heat pathogens, clear lung qi dispersing gas recovers lung and defends Xuan Fasu and fall normal.
We are utilization modern science and technology method fully, is studying hard theory of Chinese medical science, understands and cures tame academic thought at all times, sums up under the clinical dialectical treatment experience prerequisite, sets about development and getting with the experiment many-side from clinical.It is treatment flu definite effective new drug.Whole prescription good fortune cold is induced sweat, heat-clearing and toxic substances removing, by epidemic febrile disease from the beginning of suitable.Fructus Forsythiae, Herba Andrographis heat-clearing and toxic substances removing are eliminated pathogenesis emphatically in the side, are our principal agent.Compatibility Herba Commelinae, Herba Menthae, Rhizoma Et Radix Notopterygii a surname send out and defend gas, the table that dispels the heat, wind-expelling pain-stopping; The Radix Trichosanthis clearing away heat and promoting production of body fluid both can strengthen heat clearing away strength, can replenish impaired cloudy Tianjin again.Be equipped with a little hot using warming therapy product in the hot cold of we, both be beneficial to expelling pathogenic factors from the exterior, do not carry on the back the purport of hot cold again.
The objective of the invention is to realize by following measures:
A kind of Chinese medicine preparation for the treatment of flu, it is to be prepared from by following bulk drugs material:
5～20 parts of Fructus Forsythiaes, 5～20 parts of Herba Andrographis, 4～20 parts of Rhizoma Et Radix Notopterygiis, 4～20 parts of Herba Commelinaes, 2～15 parts of Herba Menthaes, 2～15 parts of Radix Trichosanthis.
The Chinese medicine preparation of described treatment flu, it is to be prepared from by following bulk drugs material:
12 parts of Fructus Forsythiaes, 12 parts of Herba Andrographis, 6 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Herba Commelinaes, 6 parts of Herba Menthaes, 10 parts of Radix Trichosanthis.
The Chinese medicine preparation of described treatment flu, its dosage form is a said dosage form on any medicament.
The Chinese medicine preparation of described treatment flu, its dosage form can be granule, tablet, capsule, powder, pill, syrup.
The Chinese medicine preparation of described treatment flu, its dosage form can be a granule.
The Chinese medicine preparation of described treatment flu, its preparation technology may further comprise the steps:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues, aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in medicinal residues, aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
Beneficial effect of the present invention:
The present invention tests used medicine according to embodiment 1 preparation, to call the doubly-linked cold granules in the following text.
One, the pharmacodynamic experiment of medicine of the present invention:
(1) the doubly-linked cold granules influence cough caused to ammonia
[1]
Get 50 of mices, male and female half and half, body weight 18-22g.Be divided into 5 groups at random, 10 every group.Be model control group, positive controls, the high, medium and low dosage group of doubly-linked cold granules.The high, medium and low dosage group of doubly-linked cold granules gives 22.4g/kg, 11.2g/kg, 5.6g/kg respectively, and positive controls gives codeine 50mg/kg, and the administration volume is 0.4ml/20g.Model control group gives isopyknic distilled water.Give every day and irritate the stomach medicine once, successive administration 5 times, after the last administration, mice placed in the 500ml glass bell jar in one hour, connect the glass fog-spray nozzle by gas compressor, spray into ammonia (25%-28% ammonium hydroxide) in the bell jar equably with the 400mmHg constant voltage, sprayed 5 seconds, and observed and write down and respectively organize the number of times of coughing in mouse cough incubation period and 2 minutes.The result is organized a t check, see Table 1.
The influence (n=10) cough caused to ammonia of table 1, doubly-linked cold granules (X ± S)
| Group | Dosage (g/kg) | Incubation period (second) | Two minutes cough number of times |
| Model contrast codeine doubly-linked cold granules | - 0.05 22.4 11.2 5.6 | 23.1±7.5 45.5±12.2** 43.9±6.7** 39.0±9.1* 26.8±8.8 | 66±17 37±9** 40±16** 49±10** 59±16 |
* P＜0.05, * * P＜0.01, with model control group relatively
By table 1 as seen, doubly-linked cold granules height, middle dosage group can prolong the cough latent period of the cough caused mice of ammonia, also can reduce the cough number of times (P＜0.05, P＜0.01) of mice in two minutes.Low dose group does not have obvious influence to above-mentioned two indexs.
(2) the doubly-linked cold granules causes the influence of Cavia porcellus asthma to acecoline and histamine phosphate
[2]
Get Cavia porcellus childhood (body weight 250-300g), put into glass bell jar (volume is about 4L), spray into 2% acecoline and 15 seconds of 0.1% histamine phosphate isometric(al) mixed liquor with the pressure of 400mmHg, observe drawing of Cavia porcellus and breathe heavily incubation period (promptly beginning to be the devil) until the time that tic is fallen to asthma attack, breathing from spraying.Overview 6 minutes (360 seconds), the person of keeping one's legs draws and breathes heavily incubation period and calculated with 360 seconds.Get to draw and breathe heavily 40 of Cavia porcelluss that are no more than 120 seconds incubation period, be divided into 5 groups incubation period at random, 8 every group by drawing to breathe heavily.Model control group, positive controls, the high, medium and low dosage group of doubly-linked cold granules.The high, medium and low dosage group of doubly-linked cold granules gives 7.4g/kg, 3.7g/kg, 1.85g/kg respectively, and positive controls gives aminophylline 0.13g/kg, and the administration volume is 0.5ml/100g.Model control group gives isopyknic distilled water.Give to irritate the stomach medicine every day once, successive administration 5 times was measured to draw after the last administration and is breathed heavily incubation period in 1 hour once more, and measurement result is carried out statistical procedures, saw Table 2.
Table 2, doubly-linked cold granules are to acecoline and histamine phosphate
Cause influence (the n=8) (X ± S) of Cavia porcellus asthma
| Group | Dosage (g/kg) | Draw and breathe heavily incubation period (second) |
| Model contrast aminophylline doubly-linked cold granules | - 0.13 7.40 3.70 1.85 | 95.2±13.0 352.5±10.1** 147.0±22.9** 112.3±16.4* 100.4±18.7 |
* P＜0.05, * * P＜0.01, with model control group relatively
By table 2 as seen, doubly-linked cold granules height, middle dosage group and aminophylline group can the significant prolongation acecolines and histamine phosphate Cavia porcellus asthma incubation period (P＜0.05, P＜0.01) of causing.Low dose group does not have tangible prolongation effect.
(3) influence of rat paw edema due to the doubly-linked cold granules on Carrageenan
[3]
Get 40 of male rats, body weight 140-160g is divided into 5 groups at random by body weight, 8 every group.Model control group, positive controls, the high, medium and low dosage group of doubly-linked cold granules.The high, medium and low dosage group of doubly-linked cold granules gives 11.2g/kg, 5.6g/kg, 2.8g/kg respectively, and positive controls gives aspirin 0.1g/kg, and the administration volume is 1ml/100g.Model control group gives isopyknic distilled water.Give every day and irritate the stomach medicine once, successive administration 5 times is measured every Mus right hind normal foot sole of the foot volume with the glass container method before administration last day.After measuring normal foot sole of the foot volume, each group administration respectively, only causes inflammation at rat right hind leg foot plantar subcutaneous injection 1% carrageenin suspension 0.1ml/ respectively at half an hour after the administration.Subsequently, all by last method, each surveyed once sufficient sole of the foot volume every 1 hour, and continuous 6 times, the record result, and be calculated as follows swelling rate (%) respectively.Measurement result is carried out statistical procedures.The results are shown in Table 3.
The influence (n=8) of rat paw edema due to table 3, the doubly-linked cold granules on Carrageenan (X ± S)
| Group | Dosage (g/kg) | Swelling rate (%) | |||||
| 1h | 2h | 3h | 4h | 5h | 6h | ||
| Model contrast aspirin doubly-linked cold granules | 0.1 11.2 5.6 2.8 | 40.3± 15.5 16.4± 11.8** 13.0± 20.2** 19.7± 11.4* 39.5± 23.1 | 74.2± 51.1 18.5± 4.6** 18.5± 15.1** 24.3± 21.8* 69.9± 28.6 | 119.9 ±96.9 22.4± 11.7* 38.9± 23.9* 67.2± 20.3 75.4± 26.7 | 164.2 ±90.0 31.2± 13.7** 60.1± 25.9** 107.7 ±29.6 107.9 ±47.6 | 157.0± 82.9 56.4± 31.8** 79.9± 30.7* 109.2± 25.1 123.4± 26.7 | 149.9± 64.4 68.1± 41.0** 70.6± 32.5** 77.6± 32.4* 136.3± 35.4 |
* P＜0.05, * * P＜0.01, with model control group relatively
By table 3 as seen, doubly-linked cold granules high dose group can reduce by rat paw edema inflammation degree due to the carrageenin (P＜0.05, P＜0.01) at 1h～6h; Middle dosage group can obviously reduce when 1h～2h and 6h by rat paw edema inflammation degree (P＜0.05) due to the carrageenin; Low dose group does not have the effect of obvious inhibition pedal swelling.
(4) the doubly-linked cold granules is to 2, the influence of rat fever due to the 2, 4-dinitrophenol
[4]
Get the male rat of body weight 150-170g, laboratory temperature is controlled between 24-26 ℃, surveys normal body temperature with mercury clinical thermometer (anus thermometre), surveys every day 2 times, continuous 3 days, fasting is 8 hours before the experiment, and experiment day is per hour surveyed once continuous 3 times, with 3 body temperature meansigma methodss as normal body temperature, get body temperature change less than 50 of 0.3 ℃ rats, be divided into 5 groups at random, 10 every group.Model control group, positive controls, the high, medium and low dosage group of doubly-linked cold granules.The high, medium and low dosage group of doubly-linked cold granules gives doubly-linked cold granules 11.2g/kg, 5.6g/kg, 2.8g/kg respectively, and positive controls gives aspirin 0.1g/kg, and the administration volume is 1ml/100g.Model control group gives isopyknic distilled water.30min behind the gastric infusion, 2 of every Mus back subcutaneous injection 0.15%, 2, 4-dinitrophenol 15mg/kg (preparing) with normal saline, every 20min surveys the anus temperature once after pyrogenicity, surveys 3h continuously, the fervescence value of each time point after the calculating pyrogenicity, and the processing that takes statistics, the results are shown in Table 4.
Table 4, doubly-linked cold granules be to 2,2, 4-dinitrophenol
Due to influence (the n=10) (X ± S) of rat fever
| Group | Dosage (g/kg) | The fervescence value (℃) | ||||||||
| 20 | 40 | 60 | 80 | 100 | 120 | 140 | 160 | 180 | ||
| Model contrast aspirin doubly-linked cold granules | 0.1 11.2 5.6 2.8 | 0.85± 0.49 0.33± 0.20** 0.31± 0.21* 0.55± 0.34 0.48± 0.27 | 1.08± 0.35 0.28± 0.24** 0.26± 0.24* 0.73± 0.29 0.91± 0.36 | 1.51± 0.43 0.23± 0.16** 0.29± 0.14** 0.89± 0.40* 1.01± 0.32* | 1.37± 0.38 0.36± 0.15** 0.31± 0.22** 0.78± 0.33* 0.98± 0.29* | 1.33± 0.38 0.54± 0.22** 0.34± 0.19** 0.75± 0.25** 0.94± 0.25* | 1.19± 0.37 0.55± 0.27** 0.43± 0.20** 0.67± 0.36* 0.91± 0.40 | 1.08± 0.34 0.34± 0.17** 0.29± 0.21* 0.60± 0.33 0.88± 0.41 | 0.95± 0.33 0.25± 0.29** 0.29± 0.20* 0.66± 0.34 0.82± 0.45 | 0.95± 0.36 0.19± 0.26** 0.20± 0.22* 0.59± 0.35 0.66± 0.29 |
* P＜0.05, * * P＜0.01, with model control group relatively
By table 4 as seen, the model control group rat temperature promptly rises in 20min, reaches the peak to 60min, individual animal peak fervescence＞2 ℃, and fervescence continues more than 3 hours.Doubly-linked cold granules high dose group rat temperature raises and is subjected to obvious inhibition (P＜0.01) at 20min～3h; Middle dosage group rat temperature raises and is subjected to obvious inhibition (P＜0.01) at 1h～2h; The rat temperature of low dose group raises and is subjected to obvious inhibition (P＜0.01) at 1h～100min.
(5) the doubly-linked cold granules is to the influence of mice carbon clearance experiment
[4]
Mice is divided into 5 groups (10 every group) at random: negative control group, positive controls, be subjected to the high, medium and low dosage group of reagent, each group is irritated stomach equal-volume distilled water, krestin (0.8g/kg), doubly-linked cold granules (22.4,11.2,5.6g/kg) respectively.The administration volume is 0.4ml/20g.Administration every day 1 time, totally 5 times.After the last administration 30 minutes, tail vein injection india ink 0.05ml/10g got blood 20ul from the eye socket venous plexus respectively in 1min and 5min, is added to 2ml 0.1%Na
2CO
3Shake up in the solution, with 721 type spectrophotometers colorimetric under 680nm, photometry density (the following OD that uses respectively
1And OD
5The optical density of expression 1min and 5min institute blood sampling) is calculated as follows and cleans up index K value (the results are shown in Table 5).
K＝(logOD
1-logOD
5)/(t
5-t
1)＝(logOD
1-logOD
5)/4
The K value after body weight and liver spleen heavily convert, phagocytic index α value:
The heavy * K of phagocytic index α=body weight/liver spleen
1/3
Table 5 doubly-linked cold granules is to the influence (n=10) of clearance in mice index and phagocytic index (x ± s)
| Group | Dosage (g/kg) | Clean up index K | Phagocytic index α |
| Negative control group positive controls doubly-linked cold granules | 0.8 22.4 11.2 5.6 | 0.0297±0.011 0.0445±0.012** 0.0435±0.013** 0.0424±0.012* 0.0319±0.012 | 4.635±0.644 5.377± 0.607** 5.359± 0.581** 5.247±0.829 4.742±0.741 |
Annotate: * P＜0.05, compare with negative control group * * P＜0.01
The result shows, what doubly-linked cold granules 22.4g/kg dosage group can the utmost point improves mice significantly cleans up index and phagocytic index (P＜0.01).Doubly-linked cold granules 11.2g/kg dosage group is the tool exponential work of clearance in mice (P＜0.05) that improves also.
(6) the doubly-linked cold granules is to the influence of dinitrofluorobenzene (DNFB) induced mice delayed allergy
[7]
Fresh preparation 1%DNFB5ml: take by weighing DNFB50mg, the medicine that takes by weighing is put in the clean vial, with the acetone Oleum Sesami solution (acetone: Oleum Sesami=1: 1) pour in the bottle, build blended rubber cloth and seal for preparing in advance, behind the mixing, take by bottle cap with the syringe of 250ul and to get final product.
Administration: the ICR mice is divided into six groups (10 every group) at random: high, medium and low dosage group is gastric infusion doubly-linked cold granules (22.4,11.2,5.6g/kg) respectively, positive controls is given krestin (0.8g/kg), negative control group is irritated with distilled water, the administration volume is 0.4ml/20g, and other establishes a sensitization group not.
Sensitization: administration is after 2 days, except that sensitization group not, and every Mus abdominal part unhairing, the about 3 * 3cm of scope
2Size, and 1%DNFB solution 0.05ml is applied in.
The generation of delayed allergy and mensuration: after the sensitization the 5th day, the DNFB solution 10ul with 1% evenly was applied in mouse right ear (two sides) and attacks, and the sensitization group is not coated with ear equally.Attacked 24 hours, mice is put to death in cervical vertebra dislocation, takes off the auricle of diameter 8mm with card punch, weighs, and the difference of left and right sides auricle weight is the swelling degree.The results are shown in Table 6.
The influence (n=10) of the mice delayed allergy that table 6 doubly-linked cold granules brings out DNFB (x ± s)
| Group | Dosage (g/kg) | Swelling degree (mg) |
| Sensitization group negative control group krestin doubly-linked cold granules not | 0.8 22.4 11.2 5.6 | 1.25±0.39** 4.28±0.51 6.23±0.71** 6.19±0.82** 5.36±0.54* 5.23±0.48* |
* P＜0.05, * * P＜0.01 and negative control group comparison
The result shows, doubly-linked cold granules 22.4g/kg dosage group can significantly improve swelling degree (P＜0.01) by the utmost point, 11.2g/kg, 5.6g/kg dosage group all can significantly improve Mus ear swelling degree (P＜0.05), illustrates that the doubly-linked cold granules has the effect that strengthens the mice specific cellular immunity.
(7) the doubly-linked cold granules is to the influence (serum hemolysin method) of mice specific humoral immunity experiment
[8,9]
Select 50 of ICR mices, be divided into five groups at random, high, medium and low dosage group is gastric infusion doubly-linked cold granules (22.4,11.2,5.6g/kg) respectively, and positive group is given krestin (0.8g/kg), and negative control group is irritated with distilled water.The administration volume is 0.4ml/20g.
Immunity: administration is after 3 days, mouse peritoneal injection 20%SRBC 0.2ml/ only, the immunity back was plucked eyeball on the 4th day and is got blood, separation of serum, dilute 500 times after for mensuration.
Hemolytic reaction: add diluted serum 1ml in the reaction tube successively, 5%SRBC 0.5ml, 10% complement 1ml, put in 37 ℃ of water-baths and be incubated 30 minutes, move to cessation reaction in the ice bath then, centrifugal 10 minutes of 1500rpm gets supernatant 1ml and adds Dou Shi reagent 3ml, shake up and placed 10 minutes, read absorbance in 540nm wavelength colorimetric.
The SRBC half hemolysis value: get 5%SRBC 0.25ml and add Dou Shi reagent to 4ml, colorimetric reads absorbance, the absorbance when being used SRBC HD50 in the experiment.
Calculate: the clear HC of sample cell HD50
50Be calculated as follows:
HC
50Absorbance * 500 (the results are shown in Table 7) during the absorbance of=sample/SRBC HD50
The influence (n=10) that table 7 doubly-linked cold granules is tested the mice specific humoral immunity (x ± s)
| Group | Dosage (g/kg) | HC 50 |
| Negative control krestin doubly-linked cold granules | 0.8 22.4 11.2 5.6 | 242.57±38.86 324.90±52.81** 301.36±40.96** 295.47±46.49* 268.37±48.19 |
* P＜0.05, * * P＜0.01, with matched group relatively
The result shows that doubly-linked cold granules height, middle dosage group significantly improve HC
50Value can significantly strengthen mice specific humoral immunity (P＜0.01, P＜0.05).
(8) the doubly-linked cold granules is to the test of pesticide effectiveness in the body of influenza virus Mus lung adapted strain FM1 strain induced mice pneumonia
1, viral vitality test
Getting influenza virus Mus lung adapted strain FM1 strain is inoculated in 6 Embryo Gallus domesticus of 9 ages in days, gather in the crops allantoic fluid at 37 ℃ after hatching 48h, tiring of allantoic fluid is respectively 1: 1024 in 6 Embryo Gallus domesticus that record with the blood clotting method, 1: 256,1: 1024,1: 1024,1: 256,1: 512,6 parts of allantoic fluids are merged the back as stock solution.
2, the doubly-linked cold granules is to the therapeutical effect of influenza virus Mus lung adapted strain FM1 strain induced mice pneumonia
(1) mensuration of influenza virus virulence:
Get 50 white mice, be divided into 5 groups at random, 10 every group, male and female half and half.With influenza virus Mus lung adapted strain FM1 strain suspension collunarium infecting mouse 30ul/ only, each is organized mouse infection viral dilution degree and is respectively 1 (stock solution), 10-1,10-2,10-3,10-4 under the shallow degree anesthesia of ether.Observed 15 days continuously behind the mouse lung influenza virus infection, write down animal dead number and death time and performance every day.Press the LD that the Bliss method is calculated influenza virus Mus lung adapted strain FM1 strain infecting mouse pulmonary
50And 95% fiducial limit.
The result shows: beginning in the 4th day death successively after each treated animal pulmonary infection influenza virus Mus lung adapted strain FM1 strain, animal is no longer dead after the 10th day.Each treated animal per cent death loss is respectively 100%, 70%, and 60%, 30%, 20%.Each dead animal is myasthenia of limbs after influenza virus infection Mus lung adapted strain FM1 strain, then dyspnea and death.The LD of mouse lung influenza virus infection FM1 strain
50Be 0.0044, the 95% credible 0.0006-0.0315 that is limited to.
(2) to the therapeutical effect of influenza virus Mus lung adapted strain FM1 strain induced mice pneumonia
The doubly-linked cold granules is set high, medium and low three dosage groups, and concentration is respectively 1.0g crude drug/ml, 0.5g crude drug/ml, 0.25g crude drug/ml, and 0.4ml/20g calculates using dosage according to every mice use amount and is respectively 20,10 and the 5g crude drug/kg).Virazole is 25.0mg/kg.Get 60 healthy mices, be divided into 5 groups at random: the high, medium and low dosage group of doubly-linked cold granules, virazole group, model control group, every group of 12 mices, male and female half and half.Is 100LD with above-mentioned influenza virus Mus lung adapted strain FM1 strain virus stock solution through suitably diluting
50Concentration, collunarium infects respectively organizes mouse lung, 30 μ l/ only.Each administration group mice is 2h after infecting, respectively at the high, medium and low dosage doubly-linked of mice nasal-cavity administration cold granules, and virazole intramuscular injection (0.5ml/ is only), the virus control group is given normal saline.Administration 5 days, every day 3 times, each 3h at interval observed 15 days after the administration continuously.Write down death toll and death time after the mouse infection virus every day, calculate dead protective rate and prolong vital rates: dead protective rate=virus control group mortality rate-experimental group mortality rate; Prolong on average life number of days * 100% of vital rates=(experimental group on average life number of days-virus control group on average life number of days)/virus control group.Experimental result sees Table 8.
Table 8 doubly-linked cold granules is to the therapeutical effect of influenza virus induced mice pneumonia
| Experimental group (n=12) | Dosage (the g crude drug/kg) | Mortality rate (%) | Dead protective rate (%) | Mean survival time (my god) | Prolong vital rates (%) |
| The contrast of doubly-linked cold granules virazole model | 22.4 11.2 5.6 0.025 - | 16.7 41.7 83.3 16.7 100 | 83.3 58.3 16.7 83.3 | 11.5 10.6 9.3 13 7 | 64.3 51.4 32.9 85.7 |
The result shows that high, medium and low dosage doubly-linked cold granules all can reduce the animal dead rate, and the natural law of on average surviving prolongs, along with the dosage increase effect increase of medicine, be dose-dependence, and the model control group animal is after 4 days, animal obviously becomes thin, dyspnea, and beginning is dead.From experimental result, (22.4g crude drug/dead protective rate kg) is suitable with the effect of increase in life span and virazole (25.0mg/kg) for the doubly-linked cold granules.
3. the doubly-linked cold granules is to the influence of viral pathological changes of mouse lung and viral propagation
(1) the doubly-linked cold granules is to the influence of the viral pathological changes of mouse lung:
Get 72 of healthy mices, be divided into the high, medium and low dosage group of doubly-linked cold granules at random, virazole group, model control group and normal control group, every group of 12 mices, male and female half and half.Use 10LD
50Influenza virus drop nose infects respectively organizes mouse lung except that the normal control group, the normal control group is given normal saline, and 30 μ l/ only.Infect back 2h, except that matched group each group respectively at the high, medium and low dosage doubly-linked of mice nasal-cavity administration cold granules (22.4,11.2 and the 5.6g crude drug/kg), virazole intramuscular injection 25.0mg/kg, administration 5 days, every day 3 times, each interval 3h.Observed 5 days continuously behind the infective virus, the 6th day dissection mice got lung and weighs, and calculates the lung index.The lung index is: lung weight/body weight * 100; Write down the pulmonary lesion integration simultaneously, the results are shown in Table 9.Pneumonopathy range degree is pressed following standard integral:
0 minute: lung tissue was normal.
1 minute: a small amount of inflammatory cell or congested point appearred in lung tissue.
2 minutes: block inflammation or congested piece appearred in lung tissue.
3 minutes: half inflammation of lung tissue, congested piece or erosion.
4 minutes: most of inflammation, hyperemia or be liver-coloured.
Table 9 doubly-linked cold granules is to the influence of the viral pneumonopathy range of mice degree
| Group | Dosage (the g crude drug/kg) | Lung index (meansigma methods) | Pneumonopathy range degree (meansigma methods) |
| Doubly-linked cold granules virazole model control group normal control group | 22.4 11.2 5.6 0.025 - - | 1.32 1.27 1.65 1.15 1.80 0.81 | 0.74 1.43 2.07 0.81 2.90 0 |
The result shows: each dosage group of doubly-linked cold granules all has tangible reduction effect to pneumonopathy range degree and the effect of lung index, and its effect is suitable with positive control drug papova azoles group.
(2) the doubly-linked cold granules is to the influence of the viral propagation of mouse lung:
Get a certain amount of lung of above-mentioned animal subject, with the homogenate of 5ml normal saline, centrifugal 10 minutes of 1500rpm, supernatant adopt the blood clotting method to measure virus titer.The results are shown in Table 10.
Table 10 doubly-linked cold granules is to the influence of the viral propagation of mouse lung
| Group | Dosage (the g crude drug/kg) | Virus titer (lgX) | Inhibition index |
| Doubly-linked cold granules virazole papova matched group | 22.4 11.2 5.6 0.025 - | 0.98 1.81 2.20 0.60 5.79 | 4.81 3.98 3.59 5.19 |
The result shows: the high, medium and low dosage group of doubly-linked cold granules, virazole intramuscular injection group, and pulmonary's virus titer all significantly is lower than the virus control group, and inhibition index (virus titer of the virus titer-experimental group of virus group) is 3.59-4.81.The effect of doubly-linked cold granules and virazole group are suitable substantially.
(9) the external resisiting influenza virus Mus of the doubly-linked cold granules lung adapted strain FM1 strain test of pesticide effectiveness
1, cell strain: people's embryo integumentary musculature fibroblast strain (self-built strain) of going down to posterity.
2, virus: FM1 virus chick embryo allantoic liquid is done 10 times of serial dilutions.
3, tissue culture's toxicity trial: with trial drug 1: 10,1: 100,1: 200,1: 400, after the dilution in 1: 800, promptly drug level is: 450mg crude drug/ml, 45mg crude drug/ml, 22.5mg crude drug/ml, 11.25mg crude drug/ml, 5.625mg crude drug/ml join cell monolayer.Measuring nontoxic boundary is 1: 400, i.e. 11.25mg crude drug/ml.
4, processing method and result: see Table 11.
The external resisiting influenza virus Mus of table 11 doubly-linked cold granules lung adapted strain FM1 strain processing method and result
| Processing method | Time (hr) | Blood cell absorption (Hd) | Hemagglutinative titer (HA) |
| Sample 2mg crude drug/ml anticipates cell sample 1mg crude drug/ml and anticipates cell sample 2mg crude drug/ml and add FM1 and put 4 ℃ and add cell biased sample 1mg crude drug/ml after spending the night and add FM1 and put 4 ℃ and add cell biased sample 2mg crude drug/ml after spending the night and add to add simultaneously behind the FM1 and add simultaneously the contrast of cell mixed model contrast control cells after cell biased sample 1mg crude drug/ml adds FM1 | 48 72 48 72 | - + - + - - - - ++ - - | 4 8 4 8 2 4 2 4 16 - - |
Can know from experimental result: sample and viral FM1 mix to be put 4 ℃ and adds cell after spending the night and mix, and sample adds and add cell simultaneously behind the viral FM1 and mix, and antiviral effect is best.Sample 11.25mg crude drug/ml group is compared with the virus control group, and hemagglutinative titer will hang down 8 times.
(10) the doubly-linked cold granules is to the antibiotic test of pesticide effectiveness of common clinical bacteria
The doubly-linked cold granules is measured the antibacterial activity in vitro of common clinical bacteria
The test of doubly-linked cold granules in-vitro antibacterial, employed culture medium is general MH culture medium (shanghai Medicine chemistry institute product) in the test.Must add 5% defat Sanguis caprae seu ovis (solid agar culture medium) or sheep blood serum (fluid medium) to higher bacterial strain of nutritional requirement such as Diplococcus pneumoniae etc.
1, adopt the double dilution method of agar to measure minimum inhibitory concentration (MIC)
(1) preparation of pastille flat board
Precision is quantitatively measured test specimen, carries out doubling dilution with an amount of physiological saline solution, makes each medicinal liquid become a series of Concentraton gradient, is successively: 1000,500,250,125,62.5,31.25,15.625,7.81,3.91,1.95 (the mg crude drug/ml).Get each gradient medicinal liquid 2ml then, join respectively in the aseptic plate (plate diameter 9cm), add the MH culture medium 18ml of insulation in 55 ℃ of water-baths that has sterilized and melted again, abundant immediately mixing, stand-by after the condensation.Like this, the ultimate density of the dull and stereotyped Chinese medicine of each pastille is followed successively by: 100,50,25,12.5,6.25,3.125,1.563,0.781,0.391,0.195 (the mg crude drug/ml).Establish blank simultaneously, only add the agar culture medium of 20ml.
(2) preparation of test organisms liquid and dibbling
Activatory each test strain is inoculated into respectively in the 2ml culture fluid in advance, 37 ℃ of overnight incubation, and the corresponding culture fluid of reuse is made suitable dilution, makes bacterial concentration be about 107-108 (CFU.ml-1).Control bacterial concentration method: with the optical density of spectrophotometric determination culture fluid, make suitable dilution then, on the MH of each pastille culture medium flat plate, blank carries out simultaneously with each test organisms of multiple spot inoculation instrument dibbling.Every some bacteria containing amount is about 104-105 (CFU).37 ℃, cultivated 24 hours, observe and write down the MIC value of each bacterium, and calculate MIC50 and MIC90.The results are shown in Table 12.
The external antibacterial tests result to 108 strain clinical bacteria strains of table 12 doubly-linked cold granules (the MIC:mg crude drug/ml)
| Strain | The strain number | The MIC scope | MIC50 | MIC90 |
| The bloodthirsty hemophilus influenza Diplococcus pneumoniae of staphylococcus aureus e coli bacillus pyocyaneus shigella flexneri | 26 23 14 17 13 15 | 0.625-10 1.25-40 10-＞80 0.625-20 0.313-10 0.625-20 | 1.25 5 ＞80 1.25 1.25 2.5 | 10 40 ＞80 20 10 20 |
Experimental result can be known from table: the doubly-linked cold granules external to test strain except bacillus pyocyaneus, certain antibacterial activity is all arranged, wherein slightly strong to the antibacterial activity of staphylococcus aureus, shigella flexneri, bloodthirsty hemophilus influenza.
(11) doubly-linked cold granules is to antibacterial tests in the body of mouse infection staphylococcus aureus
Prerun: get 70 of white mice, male and female half and half, be divided into 7 groups at random, 10 every group, 7 groups of each inoculation, 7 groups bacterial strain concentration is respectively: 1010,109,108,107,106,105,104 (CFU/ml), the lumbar injection infecting mouse, every mouse inoculation bacterium liquid 0.5ml, the dead mouse situation behind the observation inoculation bacterium in the 48h, determine that antibacterial causes the minimum bacteria suspension concentration of white mice all dead (100% death), i.e. minimum lethal dose (100%MLD).Bacterium liquid all dilutes with the culture fluid of 5% gastric Mucin.
The 100%MLD of experimental strain (CFU/ml) measurement result is as follows:
Staphylococcus aureus: 109CFU/ml.
After determining 100%MLD, carry out formal bacterium infecting mouse treatment protectiveness test.Get 70 of mices, male and female half and half are divided into 7 groups at random by body weight, 10 every group, each organize mice respectively 2 times of minimum lethal doses in prerun, determining of lumbar injection bacteria suspension 0.5ml/ only.In 7 groups of mices, 1 group of test strain infection model group, 6 groups of doubly-linked cold granules.Mice is distinguished each medicinal liquid (0.25ml/10g Mus) of gastric infusion isometric(al) variable concentrations at once after infection.Between the agent of each medicine gradient than being 1: 0.7.The infection model matched group gives isometric aseptic injection normal saline solution.The reaction of observation mice, the death toll of mice was observed 7 days continuously after record infection inoculation and the administration, pressed the medicine median effective dose ED of Bliss method calculating to infectious bacteria
50And 95% fiducial limit.The results are shown in Table 13.
Table 13 doubly-linked cold granules gastric infusion is to the endogenous protective result of the test of infection of staphylococcus aureus mice
| Group | Dosage (g/kg) | Log10 dose | Test mice number (only) | Dead mouse number (only) | Mortality rate (%) | Experiment probit | ED 50And 95% fiducial limit (g/kg) |
| 123456 model group | 16 11.2 7.84 5.49 3.84 2.69 - | 1.2 1.05 0.89 0.74 0.58 0.43 | 10 10 10 10 10 10 10 | 2 2 4 5 8 9 10 | 90 80 50 40 20 20 100 | 4.16 4.16 4.75 5 5.84 6.28 | 6.60 (5.29-8.24) |
Doubly-linked cold granules gastric infusion is to the ED of infection of staphylococcus aureus mice
50Be the 6.60g/kg crude drug, the 95% credible 5.29-8.24g/kg that is limited to.
Two, medicine acute toxicity testing of the present invention
1. be subjected to the reagent thing
Title: the doubly-linked cold granules, lot number: 050201, its extractum of this experiment is sepia.
Concentration: 6.0g crude drug/ml; Solvent: distilled water
The medicine preparation is faced with preceding with the medicinal liquid of distilled water diluting to desired concn.
2. experimental animal:
Kunming mouse, body weight 18-22g, male and female half and half, are supplied with quality certification numbering: SCXK (Soviet Union) 2001-0001 by totally 20 by animal housing of China Medicine University.
3. test method:
Get 20 of above-mentioned qualified mices, fasting is gastric infusion (consistent with the clinical application approach) after 12 hours, and dosage is the 4.8g/0.8ml/20g crude drug, is maximum drug level, and the maximum body of stomach of irritating is long-pending, the administration secondary, and respectively give once morning and afternoon.Observe mice activity and death condition every day after the administration, observed continuously 14 days.
4. result of the test:
The result shows, mice is movable normal after administration, do not find mice on the feed, breathe aspects such as heart rate, chroma of hair and feces unusual.Observe continuously 14 days mices after the administration and death do not occur, the maximum dosage-feeding that shows the doubly-linked cold granules is the 480g/kg crude drug, intend consumption for clinical people 516 times.
5. computational methods:
Body weight for humans is in 60kg, people's consumption: 0.93g crude drug/kg/ day, and mice maximum dosage-feeding every day is 480g crude drug/kg, is calculated as follows, mice maximum dosage-feeding every day is 516 times that clinical people intends consumption.
480g/Kg ÷ 0.93g/kg=516 doubly
6. conclusion:
It is the 480g/kg crude drug that mouse stomach is given the maximum dosage-feeding of doubly-linked cold granules, and clinical people intends 516 times of consumption for every day.
The specific embodiment
The invention will be further elaborated by the following examples.
Embodiment 1
Prescription: 12 parts of Fructus Forsythiaes, 12 parts of Herba Andrographis, 6 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Herba Commelinaes, 6 parts of Herba Menthaes, 10 parts of Radix Trichosanthis.
Preparation technology:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in the medicinal residues aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
Embodiment 2
Prescription: 10 parts of Fructus Forsythiaes, 10 parts of Herba Andrographis, 9 parts of Rhizoma Et Radix Notopterygiis, 9 parts of Herba Commelinaes, 4 parts of Herba Menthaes, 4 parts of Radix Trichosanthis.
Preparation technology:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in the medicinal residues aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
Embodiment 3
Prescription: 5 parts of Fructus Forsythiaes, 5 parts of Herba Andrographis, 18 parts of Rhizoma Et Radix Notopterygiis, 18 parts of Herba Commelinaes, 7 parts of Herba Menthaes, 6 parts of Radix Trichosanthis.
Preparation technology:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in the medicinal residues aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
Embodiment 4
Prescription: 20 parts of Fructus Forsythiaes, 20 parts of Herba Andrographis, 4 parts of Rhizoma Et Radix Notopterygiis, 12 parts of Herba Commelinaes, 2 parts of Herba Menthaes, 15 parts of Radix Trichosanthis.
Preparation technology:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in the medicinal residues aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
List of references
1, Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology (second edition), Beijing: People's Health Publisher, 1994; 1167
2, Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology (second edition), Beijing: People's Health Publisher, 1994; 1182
3, Qi Chen chief editor, herbal pharmacology research methodology, Beijing: People's Health Publisher, 1993:364
4, Qi Chen chief editor, herbal pharmacology research methodology, Beijing: People's Health Publisher, 1993:300
5, Qi Chen chief editor, herbal pharmacology research methodology, Beijing: People's Health Publisher, 1993:P757
6, Xu Shuyun, Bian Rulian, Chen Xiu chief editor, pharmacological experimental methodology (second edition), Beijing: People's Health Publisher, 1994; P1226
7, Qi Chen chief editor, herbal pharmacology research methodology, Beijing: People's Health Publisher, 1993:P750
8, the .P132 of bureau of drug administration of new drug (Western medicine) preclinical study guideline compilation Ministry of Health of the People's Republic of China
Claims (5)
1. Chinese medicine preparation for the treatment of flu is characterized in that it is to be prepared from by following bulk drugs material:
5～20 parts of Fructus Forsythiaes, 5～20 parts of Herba Andrographis, 4～20 parts of Rhizoma Et Radix Notopterygiis, 4～20 parts of Herba Commelinaes, 2～15 parts of Herba Menthaes, 2～15 parts of Radix Trichosanthis.
2. the Chinese medicine preparation of treatment flu according to claim 1 is characterized in that it is to be prepared from by following bulk drugs material:
12 parts of Fructus Forsythiaes, 12 parts of Herba Andrographis, 6 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Herba Commelinaes, 6 parts of Herba Menthaes, 10 parts of Radix Trichosanthis.
3. the Chinese medicine preparation of treatment flu according to claim 1 and 2 is characterized in that its dosage form is a said dosage form on any medicament.
4. the Chinese medicine preparation of treatment flu according to claim 3 is characterized in that described dosage form is granule, tablet, capsule, powder, pill, syrup.
5. the preparation technology of the Chinese medicine preparation of treatment flu according to claim 1 and 2 is characterized in that may further comprise the steps:
1) gets Fructus Forsythiae, Rhizoma Et Radix Notopterygii, Herba Menthae three flavor raw medicinal materials by described prescription, use vapor distillation, obtain volatile oil and medicinal residues aqueous solution;
2) Herba Andrographis, Radix Trichosanthis, the Herba Commelinae of the above-mentioned formula ratio of adding in the medicinal residues aqueous solution, water is carried, and is static, filters;
3) to 2) gained filtrate concentrates, and obtains extractum;
4) in extractum, add suitable adjuvant, promptly can be made into various dosage forms according to common process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100956209A CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100956209A CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1813916A true CN1813916A (en) | 2006-08-09 |
| CN100484545C CN100484545C (en) | 2009-05-06 |
Family
ID=36906348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100956209A Active CN100484545C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine compound formulation for treating common cold and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100484545C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012400A (en) * | 2015-08-10 | 2015-11-04 | 山东罗欣药业集团股份有限公司 | Soft traditional Chinese medicine composition capsules for treating cold and preparation method thereof |
| CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
-
2005
- 2005-11-25 CN CNB2005100956209A patent/CN100484545C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012400A (en) * | 2015-08-10 | 2015-11-04 | 山东罗欣药业集团股份有限公司 | Soft traditional Chinese medicine composition capsules for treating cold and preparation method thereof |
| CN105055528A (en) * | 2015-08-10 | 2015-11-18 | 山东罗欣药业集团股份有限公司 | Traditional Chinese medicine composition self-emulsifying soft capsule used for treating cold, and preparation method thereof |
| CN105055528B (en) * | 2015-08-10 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of Chinese medicine composition self-emulsifying soft capsule and preparation method thereof for treating flu |
| CN105012400B (en) * | 2015-08-10 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of Chinese traditional medicine composition composition soft capsule and preparation method thereof for treating flu |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100484545C (en) | 2009-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1207033C (en) | Traditional Chinese medicine composition for curing wind-heat type cold and its preparing method | |
| CN1947754A (en) | Medicine for treating infantile asthma and its prepn. method | |
| CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN103028001A (en) | Traditional Chinese medicine prescription for relieving asthma, relieving cough and resisting inflammatory, preparation method and application thereof | |
| CN102526568B (en) | Traditional Chinese medicine compound composition | |
| CN1813916A (en) | Compound chinese medicine formulation for treating common cold and its preparing process | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN101053600A (en) | Medicinal composition for treating cough and preparation method and application thereof | |
| CN1606979A (en) | Effect of scutellarein as antifebrile, analgesic, antiphlogistic, antibiotic and antiviral agent | |
| CN1903254A (en) | Compound medicine for treating wind-heat type cold and preparing method thereof | |
| CN1846761A (en) | Medicine for treating cold and cough and its prepn process | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1323681C (en) | Compound preparation for upper respiratory tract infection and its use in production of medicines | |
| CN1899560A (en) | Compound preparation for treating summer wet type cold and its preparing method | |
| CN1919270A (en) | Composition, exract, and pharmaceutical use thereof | |
| CN1296088C (en) | Medicine for treating acute pharyngitis of children and preparation method thereof | |
| CN1650903A (en) | Method of extracting roice clearing medicament from effective component in natural plant Chinese medicine | |
| CN1282460C (en) | Chinese traditional medieine for treating cold and preparing technique | |
| CN1742845A (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN1634413A (en) | Bastard speedwell injection and preparation method thereof | |
| CN104932726A (en) | Computer mouse foot pad with pressure relief function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. Free format text: FORMER OWNER: CHINA PHARMACEUTICAL UNIVERSITY Effective date: 20140612 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Yunman Inventor after: Wang Chunyan Inventor after: Ni Zheng Inventor after: Wu Yulin Inventor after: Pu Cunhai Inventor after: Zhang Aihua Inventor after: Fang Weirong Inventor after: Gong Xiaojian Inventor after: Li Minghua Inventor after: Li Xiaofeng Inventor before: Li Yunman Inventor before: Ni Zheng Inventor before: Wu Yulin Inventor before: Pu Cunhai Inventor before: Zhang Aihua Inventor before: Fang Weirong Inventor before: Gong Xiaojian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI YUNMAN NI ZHENG WU YULIN PU CUNHAI ZHANG AIHUA FANG WEIRONG GONG XIAOJIAN TO: LI YUNMAN NI ZHENG WU YULIN PU CUNHAI ZHANG AIHUA FANG WEIRONG GONG XIAOJIAN LI MINGHUA LI XIAOFENG WANG CHUNYAN Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 276017 LINYI, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140612 Address after: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee after: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER NAME: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210108 Address after: No.9 Tengfei Road, Yishui County, Linyi City, Shandong Province Patentee after: SHANDONG LUOXIN LEKANG PHARMACEUTICAL Co.,Ltd. Patentee after: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. Address before: Seven of 276017 Shandong city of Linyi province high tech Industrial Development Zone Patentee before: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. |